SG11201404648PA - Peptidomimetic macrocycles - Google Patents

Peptidomimetic macrocycles

Info

Publication number
SG11201404648PA
SG11201404648PA SG11201404648PA SG11201404648PA SG11201404648PA SG 11201404648P A SG11201404648P A SG 11201404648PA SG 11201404648P A SG11201404648P A SG 11201404648PA SG 11201404648P A SG11201404648P A SG 11201404648PA SG 11201404648P A SG11201404648P A SG 11201404648PA
Authority
SG
Singapore
Prior art keywords
peptidomimetic macrocycles
macrocycles
peptidomimetic
Prior art date
Application number
SG11201404648PA
Inventor
Vincent Guerlavais
Carl Elkin
Huw M Nash
Tomi K Sawyer
Bradford J Graves
Eric Feyfant
Original Assignee
Aileron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aileron Therapeutics Inc filed Critical Aileron Therapeutics Inc
Publication of SG11201404648PA publication Critical patent/SG11201404648PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
SG11201404648PA 2012-02-15 2013-02-14 Peptidomimetic macrocycles SG11201404648PA (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261599328P 2012-02-15 2012-02-15
US201261656962P 2012-06-07 2012-06-07
US201261723770P 2012-11-07 2012-11-07
PCT/US2013/026238 WO2013123266A1 (en) 2012-02-15 2013-02-14 Peptidomimetic macrocycles

Publications (1)

Publication Number Publication Date
SG11201404648PA true SG11201404648PA (en) 2014-09-26

Family

ID=48984724

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201606775YA SG10201606775YA (en) 2012-02-15 2013-02-14 Peptidomimetic macrocycles
SG11201404648PA SG11201404648PA (en) 2012-02-15 2013-02-14 Peptidomimetic macrocycles

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201606775YA SG10201606775YA (en) 2012-02-15 2013-02-14 Peptidomimetic macrocycles

Country Status (20)

Country Link
US (6) US8927500B2 (en)
EP (2) EP2822572B1 (en)
JP (3) JP6450191B2 (en)
KR (1) KR102112373B1 (en)
CN (4) CN104159595A (en)
AR (1) AR089993A1 (en)
AU (2) AU2013221432B2 (en)
BR (1) BR112014020103A2 (en)
CA (1) CA2862038C (en)
ES (1) ES2817877T3 (en)
HK (1) HK1205455A1 (en)
IL (1) IL233710B (en)
MX (1) MX362492B (en)
NZ (1) NZ627528A (en)
PH (1) PH12014501844A1 (en)
RU (2) RU2642299C2 (en)
SG (2) SG10201606775YA (en)
TW (1) TWI654207B (en)
WO (1) WO2013123266A1 (en)
ZA (1) ZA201405691B (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5656407B2 (en) 2006-12-14 2015-01-21 エイルロン セラピューティクス，インコーポレイテッド Bis-sulfhydryl macrocyclic system
CA2677045C (en) 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2564862B1 (en) 2007-02-23 2017-08-02 Aileron Therapeutics, Inc. Substituted amino acids for preparing triazole linked macrocyclic peptides
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
BRPI0918948A2 (en) 2008-09-22 2015-12-15 Aileron Therapeutics Inc peptidomimetic macrocycles
CN102223891A (en) 2008-11-24 2011-10-19 爱勒让治疗公司 Peptidomimetic macrocycles with improved properties
CA2744088A1 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102712675A (en) 2009-09-22 2012-10-03 爱勒让治疗公司 Peptidomimetic macrocycles
SI2603600T1 (en) * 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
TWI643868B (en) 2011-10-18 2018-12-11 艾利倫治療公司 Peptidomimetic macrocycles
US8987414B2 (en) * 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (en) * 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9200068B2 (en) 2012-12-18 2015-12-01 Regents Of The University Of Minnesota Compositions and methods related to tauopathy
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
US20170037086A1 (en) * 2014-04-09 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles with pth activity
AU2015320545C1 (en) * 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
WO2016049359A1 (en) * 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
MX2017011834A (en) * 2015-03-20 2018-04-11 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof.
CN106279125B (en) * 2015-06-03 2018-11-30 首都医科大学 Coumarin derivative and its preparation method
WO2017004548A1 (en) 2015-07-01 2017-01-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
US20170114098A1 (en) 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP2018528217A (en) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Peptidomimetic macrocycles as modulators of MCL-1
CR20180232A (en) 2015-10-27 2018-05-31 Hoffmann La Roche PEPTIDE MACROCICLES AGAINST ACINETOBACTER BAUMANNII
KR20180128022A (en) * 2016-03-21 2018-11-30 에일러론 테라퓨틱스 인코포레이티드 A companion diagnostic tool for peptidomimetic giant rings
EP3433261A4 (en) * 2016-03-23 2019-12-04 Dana-Farber Cancer Institute, Inc. COMPOSITIONS, ASSAYS, AND METHODS FOR TARGETING HDM2 AND HDMX TO REVERSE THE INHIBITION OF p53 IN PEDIATRIC CANCERS
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
EP3388444A1 (en) 2017-04-10 2018-10-17 F. Hoffmann-La Roche AG Anti-bacterial peptide macrocycles and use thereof
WO2019014650A1 (en) * 2017-07-13 2019-01-17 City Of Hope Anti-cancer phosphorothioate-coupled peptide conjugates and methods of using the same
WO2019084528A1 (en) 2017-10-27 2019-05-02 Ohio State Innovation Foundation Polypeptide conjugates for intracellular delivery of stapled peptides
CN112119085A (en) 2017-12-15 2020-12-22 丹娜-法伯癌症研究院有限公司 Stable peptide-mediated targeted protein degradation
US11952432B2 (en) 2018-02-07 2024-04-09 Dana-Farber Cancer Institute, Inc. Cell-permeable stapled peptide modules for cellular delivery
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20200289609A1 (en) * 2019-03-15 2020-09-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US20220267376A1 (en) * 2019-06-21 2022-08-25 Merck Sharp & Dohme Corp. P53 activator peptidomimetic macrocycles
WO2021091871A1 (en) * 2019-11-04 2021-05-14 University Of Maryland, Baltimore High affinity and dual-specificity peptide antagonists of mdm2 and mdmx for p53 activation
EP4056580A4 (en) * 2019-11-07 2023-12-06 Chugai Seiyaku Kabushiki Kaisha Method for producing peptide compound comprising highly sterically hindered amino acid
AU2020402994A1 (en) 2019-12-11 2022-06-23 Inspirna, Inc. Methods of treating cancer
WO2021222243A2 (en) * 2020-04-27 2021-11-04 Dana-Farber Cancer Institute, Inc. Structurally-stabilized and hdmx-selective p53 peptides and uses thereof
US20230279054A1 (en) * 2020-09-25 2023-09-07 University Of Washington De novo designed mixed chirality peptide macrocycles with internal symmetry
EP4228699A1 (en) 2020-10-14 2023-08-23 Dana-Farber Cancer Institute, Inc. Chimeric conjugates for degradation of viral and host proteins and methods of use

Family Cites Families (566)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1002361A (en) 1910-10-13 1911-09-05 Daniel N Baxter Boiler-cleaner.
US1002242A (en) 1910-12-27 1911-09-05 Otto P W Ehrhardt Cabbage-corer.
US4000259A (en) 1975-06-16 1976-12-28 American Home Products Corporation Cyclic dodecapeptide analogs of somatostatin and intermediates
US4438270A (en) 1977-07-11 1984-03-20 Merrell Toraude Et Compagnie α-Halomethyl derivatives of α-amino acids
US4191754A (en) 1979-02-28 1980-03-04 Merck & Co., Inc. Bicyclic somatostatin analogs
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
AU550730B2 (en) 1982-03-09 1986-04-10 Commonwealth Of Australia, The Automated metal detection
US4728726A (en) 1982-10-04 1988-03-01 The Salk Institute For Biological Studies GRF analogs IIIb
US4518586A (en) 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US5416073A (en) 1983-08-10 1995-05-16 The Adminstrators Of The Tulane Educational Fund Growth hormone-releasing peptides and method of treating animals, therewith
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5036045A (en) 1985-09-12 1991-07-30 The University Of Virginia Alumni Patents Foundation Method for increasing growth hormone secretion
US4730006A (en) 1986-01-27 1988-03-08 Merrell Dow Pharmaceuticals Inc. Derivatives of 2,6-diamino-3-haloheptanedioic acid
US4880778A (en) 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
HU906341D0 (en) 1986-10-13 1991-04-29 Sandoz Ag Process for producing peptonic derivatives modified with sugar and pharmaceutical preparatives containing these compounds as active substance
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US5112808A (en) 1987-05-11 1992-05-12 American Cyanamid Company Alkylated hormone-releasing peptides and method of treatig mammals therewith
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5877277A (en) 1987-09-24 1999-03-02 Biomeasure, Inc. Octapeptide bombesin analogs
US5453418A (en) 1988-03-07 1995-09-26 Eli Lilly And Company Ractopamine and growth hormone combinations
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
WO1989009233A1 (en) 1988-03-24 1989-10-05 Terrapin Technologies, Inc. Molecular sticks for controlling protein conformation
US5094951A (en) 1988-06-21 1992-03-10 Chiron Corporation Production of glucose oxidase in recombinant systems
US5043322A (en) 1988-07-22 1991-08-27 The Salk Institute For Biological Studies Cyclic GRF analogs
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
US5384309A (en) 1989-07-17 1995-01-24 Genentech, Inc. Cyclized peptides and their use as platelet aggregation inhibitors
US5120859A (en) 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
US5650133A (en) 1990-01-19 1997-07-22 Nycomed Salutar Macrocyclic polyaza dichelates linked through ring nitrogens via an amide or ester functionality
US5712418A (en) 1989-10-23 1998-01-27 Research Corporation Technologies, Inc. Synthesis and use of amino acid fluorides as peptide coupling reagents
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
US5580957A (en) 1989-10-30 1996-12-03 The Salk Institute For Biological Studies GnRH analogs
US5169932A (en) 1989-10-30 1992-12-08 The Salk Institute For Biological Studies Gnrh analogs
US5352796A (en) 1989-10-30 1994-10-04 The Salk Institute For Biological Studies Amino acids useful in making GnRH analogs
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5245009A (en) 1990-03-23 1993-09-14 The Salk Institute For Biological Studies CRF antagonists
CA2047042A1 (en) 1990-07-19 1992-01-20 John Hannah Cyclic hiv principal neutralizing determinant peptides
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5629020A (en) 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
AU8736691A (en) 1990-10-11 1992-05-20 Boehringer Ingelheim International Gmbh Cyclopeptides, a method of preparing them, and their use as drugs
DE69118826T2 (en) 1990-11-27 1996-11-14 Fuji Photo Film Co Ltd Propenamide derivatives, their polymers, copolymers and their use
US5124454A (en) 1990-11-30 1992-06-23 Minnesota Mining And Manufacturing Company Polycyclic diamines and method of preparation
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
JPH06505486A (en) 1991-02-07 1994-06-23 モレキュメティクス，リミティド Conformationally restricted mimetics of β-turns and β-bulges and peptides containing them
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
US5744450A (en) 1991-03-14 1998-04-28 The Salk Institute For Biological Studies GnRH analogs
WO1992018531A1 (en) 1991-04-09 1992-10-29 F. Hoffmann-La Roche Ag Growth hormone releasing factor analogs
US5262519A (en) 1991-05-15 1993-11-16 The Salk Institute For Biological Studies GRF analogs XI
US5364851A (en) 1991-06-14 1994-11-15 International Synthecon, Llc Conformationally restricted biologically active peptides, methods for their production and uses thereof
CA2072249C (en) 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
GB9114949D0 (en) 1991-07-11 1991-08-28 Smithkline Beecham Plc Novel compounds
DK0528312T3 (en) 1991-08-13 1997-12-29 Takeda Chemical Industries Ltd Cyclic peptides and their use
US7517644B1 (en) 1991-08-23 2009-04-14 Larry J. Smith Method and compositions for cellular reprogramming
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
IL103252A (en) 1991-09-30 1997-03-18 Du Pont Merck Pharma CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
EP0552417B1 (en) 1991-11-19 1999-07-07 Takeda Chemical Industries, Ltd. Cyclic peptides and use thereof
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
EP0773948A4 (en) 1992-04-03 1998-09-02 California Inst Of Techn High activity ruthenium or osmium metal carbene complexes for olefin metathesis reactions and synthesis thereof
US5411860A (en) 1992-04-07 1995-05-02 The Johns Hopkins University Amplification of human MDM2 gene in human tumors
CA2136624A1 (en) 1992-05-26 1993-12-09 Cornelis J. M. Melief Peptides of human p53 protein for use in human t cell response inducing compositions, and human p53 protein-specific cytotoxic t-lymphocytes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0651761B1 (en) 1992-07-13 2002-10-09 Bionebraska, Inc. Method for modification of recombinant polypeptides
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5371070A (en) 1992-11-09 1994-12-06 The Salk Institute For Biological Studies Bicyclic GnRH antagonists and a method for regulating the secretion of gonadotropins
WO1994018955A1 (en) 1993-02-22 1994-09-01 Alza Corporation Compositions for oral delivery of active agents
EP0691987A1 (en) 1993-03-29 1996-01-17 The Du Pont Merck Pharmaceutical Company CYCLIC COMPOUNDS USEFUL AS INHIBITORS OF PLATELET GLYCOPROTEIN IIb/IIIa
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1994025482A1 (en) 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
US5446128A (en) 1993-06-18 1995-08-29 The Board Of Trustees Of The University Of Illinois Alpha-helix mimetics and methods relating thereto
KR100325972B1 (en) 1993-08-09 2002-07-27 바이오메져 인코퍼레이티드 Therapeutic peptide derivatives
US5622852A (en) 1994-10-31 1997-04-22 Washington University Bcl-x/Bcl-2 associated cell death regulator
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
WO1995014777A1 (en) 1993-11-22 1995-06-01 Onyx Pharmaceuticals p53-BINDING POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME
US6287787B1 (en) 1993-11-24 2001-09-11 Torrey Pines Institute For Molecular Studies Dimeric oligopeptide mixture sets
JPH09511496A (en) 1994-02-18 1997-11-18 セル・セラピューティックス・インコーポレーテッド Intracellular messenger
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5824483A (en) 1994-05-18 1998-10-20 Pence Inc. Conformationally-restricted combinatiorial library composition and method
JP3166482B2 (en) 1994-06-07 2001-05-14 日産自動車株式会社 Coloring structure having reflective interference action
IL109943A (en) 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
US6407059B1 (en) 1994-06-08 2002-06-18 Peptor Limited Conformationally constrained backbone cyclized peptide analogs
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
US7553929B2 (en) 1994-06-13 2009-06-30 Vanderbilt University Cell permeable peptides for inhibition of inflammatory reactions and methods of use
US5770377A (en) 1994-07-20 1998-06-23 University Of Dundee Interruption of binding of MDM2 and P53 protein and therapeutic application thereof
US5702908A (en) 1994-07-20 1997-12-30 University Of Dundee Interruption of binding of MDM2 and p53 protein and therapeutic application thereof
RU2161042C2 (en) 1994-09-19 2000-12-27 Дж. Моро Рикардо Method for detecting and treating cancer
CA2158782C (en) 1994-09-23 2010-01-12 Pierrette Gaudreau Marker for growth hormone-releasing factor receptors
US5681928A (en) 1994-12-16 1997-10-28 The Salk Institute For Biological Studies Betides and methods for screening peptides using same
ATE544776T1 (en) 1994-12-29 2012-02-15 Massachusetts Inst Technology CHIMERIC DNA BINDING PROTEINS
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5792747A (en) 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
US6169073B1 (en) 1995-02-16 2001-01-02 Bayer Corporation Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
EP0729972A1 (en) 1995-02-28 1996-09-04 F. Hoffmann-La Roche Ag Peptide derivatives of tetrahydronaphthalene
US5675001A (en) 1995-03-14 1997-10-07 Hoffman/Barrett, L.L.C. Heteroatom-functionalized porphyrazines and multimetallic complexes and polymers derived therefrom
US6514942B1 (en) 1995-03-14 2003-02-04 The Board Of Regents, The University Of Texas System Methods and compositions for stimulating T-lymphocytes
US5700775A (en) 1995-03-24 1997-12-23 Gutniak; Mark K. Method and treatment composition for decreasing patient time in catabolic state after traumatic injury
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US6090958A (en) 1995-03-31 2000-07-18 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (en) 1995-03-31 1998-05-19 Emisphere Tech Inc Compound composition dosage unit form methods for administering a biologically active agent for preparing a composition for administering an active agent and for preparing a compound and pharmacological composition
US5731408A (en) 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
US6054556A (en) 1995-04-10 2000-04-25 The Arizona Board Of Regents On Behalf Of The University Of Arizona Melanocortin receptor antagonists and agonists
WO1996032126A1 (en) 1995-04-14 1996-10-17 The Administrators Of The Tulane Educational Fund Analogs of growth hormone-releasing factor
US5672584A (en) 1995-04-25 1997-09-30 The University Of Kansas Cyclic prodrugs of peptides and peptide nucleic acids having improved metabolic stability and cell membrane permeability
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
DK0832096T3 (en) 1995-05-04 2001-10-01 Scripps Research Inst Synthesis of proteins by native chemical ligation
US6458764B1 (en) 1995-05-26 2002-10-01 Theratechnologies Inc. GRF analogs with increased biological potency
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6020311A (en) 1995-05-26 2000-02-01 Theratechnologies, Inc. GRF analogs with increased biological potency
ES2163020T3 (en) 1995-05-26 2002-01-16 Theratechnologies Inc CHEMICAL ANALOGS OF FACTOR RELEASE OF GROWTH HORMONE (GRF) OF BODY FAT, PROVIDED WITH GREATER BIOLOGICAL POWER.
US5817789A (en) 1995-06-06 1998-10-06 Transkaryotic Therapies, Inc. Chimeric proteins for use in transport of a selected substance into cells
US6413994B1 (en) 1999-02-22 2002-07-02 The Salk Institute For Biological Studies Modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
US6051554A (en) 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5811515A (en) 1995-06-12 1998-09-22 California Institute Of Technology Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis
FR2738151B1 (en) 1995-09-04 1997-09-26 Rhone Poulenc Rorer Sa ANTAGONISTS OF THE ONCOGENIC ACTIVITY OF THE MDM2 PROTEIN, AND THEIR USE IN THE TREATMENT OF CANCERS
EP0766966A3 (en) 1995-09-08 2001-02-28 Eli Lilly And Company Method of treating insulin resistance
US5750499A (en) 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
GB9521544D0 (en) 1995-10-20 1995-12-20 Univ Dundee Activation of P53 protein and therapeutic applications thereof
US6123964A (en) 1995-10-27 2000-09-26 Merck & Co., Inc. Wet granulation formulation of a growth hormone secretagogue
US5840833A (en) 1995-10-27 1998-11-24 Molecumetics, Ltd Alpha-helix mimetics and methods relating thereto
AU722042B2 (en) * 1995-11-30 2000-07-20 Board Of Regents, The University Of Texas System Methods and compositions for the diagnosis and treatment of cancer
ES2323159T3 (en) 1995-12-22 2009-07-07 Novo Nordisk A/S COMPOUNDS WITH RELEASE PROPERTIES OF THE HORMONE OF GROWTH.
US5807983A (en) 1995-12-28 1998-09-15 The Salk Institute For Biological Studies GNRH antagonist betides
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
EP0880357A4 (en) 1996-01-17 1999-05-12 California Inst Of Techn Synthesis of conformationally restricted amino acids, peptides and peptidomimetics by catalytic ring closing metathesis
US5849954A (en) 1996-01-18 1998-12-15 Research Corporation Technologies, Inc. Method of peptide synthesis
WO1997026278A1 (en) 1996-01-18 1997-07-24 Steeno Research Group A/S Synthetic il-10 analogues
US5849691A (en) 1996-02-20 1998-12-15 The United States Of America As Represented By The Department Of Health And Human Services Peptidomimetic inhibitors of cathepsin D and plasmepsins I and II
IL126318A (en) 1996-03-29 2004-09-27 Emisphere Tech Inc Compounds and compositions for delivering active agents and some novel carrier compounds
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
JP3792777B2 (en) 1996-05-10 2006-07-05 株式会社カネカ Method for producing 1-alkoxycarbonyl-3-phenylpropyl derivative
WO1997044042A1 (en) 1996-05-22 1997-11-27 Arch Development Corporation Sleep quality improvement using a growth hormone secretagogue
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
US5817627A (en) 1996-06-14 1998-10-06 Theratechnologies Inc. Long-acting galenical formulation for GRF peptides
DK0812856T3 (en) 1996-06-14 2000-01-03 Takeda Chemical Industries Ltd Method for removing N-terminal methionine
US5663316A (en) 1996-06-18 1997-09-02 Clontech Laboratories, Inc. BBC6 gene for regulation of cell death
US7083983B2 (en) * 1996-07-05 2006-08-01 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
AU3847997A (en) 1996-07-05 1998-02-02 Cancer Research Campaign Technology Limited Inhibitors of the interaction between P53 and MDM2
AU3434697A (en) 1996-07-22 1998-02-10 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5955593A (en) 1996-09-09 1999-09-21 Washington University BH3 interacting domain death agonist
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US5965703A (en) 1996-09-20 1999-10-12 Idun Pharmaceuticals Human bad polypeptides, encoding nucleic acids and methods of use
GB9619757D0 (en) 1996-09-21 1996-11-06 Knoll Ag Chemical process
US5856445A (en) 1996-10-18 1999-01-05 Washington University Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator
JP4024309B2 (en) 1996-10-22 2007-12-19 第一三共株式会社 New treatment for infectious diseases
US6271198B1 (en) 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
AU734337B2 (en) 1996-11-21 2001-06-14 Promega Corporation Alkyl peptide amides and applications
CZ290347B6 (en) 1997-02-07 2002-07-17 Ústav organické chemie a biochemie AV ČR Cyclopeptides stimulating growth hormone release and process of their preparation
US6313088B1 (en) 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6060513A (en) 1997-02-07 2000-05-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CA2281204A1 (en) 1997-02-20 1998-08-27 Yeda Research And Development Co., Ltd. Antipathogenic synthetic peptides and compositions comprising them
US6849428B1 (en) 1997-03-05 2005-02-01 New England Biolabs, Inc. Intein-mediated protein ligation of expressed proteins
US6635740B1 (en) 1997-03-27 2003-10-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Ligand/lytic peptide compositions and methods of use
CA2286867A1 (en) 1997-04-11 1998-10-22 Eli Lilly And Company Combinatorial libraries of peptidomimetic macrocycles and processes therefor
GB9708092D0 (en) 1997-04-22 1997-06-11 Univ Dundee Materials and methods relating to inhibiting the interaction of p53 and mdm2
US6329368B1 (en) 1997-05-09 2001-12-11 The Regents Of The University Of California Endocrine modulation with positive modulators of AMPA type glutamate receptors
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
US6127341A (en) 1997-06-20 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
WO1999014321A1 (en) 1997-09-17 1999-03-25 The Walter And Eliza Hall Institute Of Medical Research Novel therapeutic molecules
US6420136B1 (en) 1997-09-26 2002-07-16 University Technologies International, Inc. Method of modulating p53 activity
US6165732A (en) 1997-10-14 2000-12-26 Washington University Method for identifying apoptosis modulating compounds
US6875594B2 (en) 1997-11-13 2005-04-05 The Rockefeller University Methods of ligating expressed proteins
WO1999029343A1 (en) 1997-12-09 1999-06-17 Thomas Jefferson University Method of treating bladder cancer with wild type vaccinia virus
JP3786832B2 (en) 1998-01-07 2006-06-14 デビオ ルシェルシュ ファルマシュティーク ソシエテ アノニム Degradable heterobifunctional poly (ethylene glycol) acrylate and gels and composites derived therefrom
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
US6030997A (en) 1998-01-21 2000-02-29 Eilat; Eran Acid labile prodrugs
JP3842042B2 (en) 1998-01-29 2006-11-08 ポリ−メド・インコーポレーテッド Absorbable microparticles
AR014069A1 (en) 1998-01-29 2001-01-31 Kinerton Ltd PROCEDURE FOR PREPARING MICROPARTICLE OR UNITED MICROPARTICLES ENCAPSULATED
CA2321026A1 (en) 1998-03-09 1999-09-16 Zealand Pharmaceuticals A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
AU767185B2 (en) 1998-03-23 2003-11-06 President And Fellows Of Harvard College Synthesis of compounds and libraries of compounds
WO1999052933A1 (en) 1998-04-15 1999-10-21 Aventis Pharmaceuticals Products Inc. Process for the preparation of resin-bound cyclic peptides
US6190699B1 (en) 1998-05-08 2001-02-20 Nzl Corporation Method of incorporating proteins or peptides into a matrix and administration thereof through mucosa
CA2319495A1 (en) 1998-06-08 1999-12-16 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
US6326354B1 (en) 1998-08-19 2001-12-04 Washington University Modulation of apoptosis with bid
US6194402B1 (en) 1998-09-02 2001-02-27 Merck & Co., Inc. Enhancement of return to independent living status with a growth hormone secretagogue
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
US6696063B1 (en) 1998-12-30 2004-02-24 Applied Research Systems Ars Holding N.V. Treatment of HIV-associated dysmorphia/dysmetabolic syndrome (HADDS) with or without lipodystrophy
DE60037394T2 (en) 1999-01-29 2009-01-02 The Board Of Trustees For The University Of Illinois, Urbana USE OF p53 INHIBITORS FOR THE TREATMENT OF SIDE EFFECTS IN CANCER THERAPY
US6372490B1 (en) 1999-02-23 2002-04-16 Curagen Corporation Nucleic acid encoding the MDM interacting protein
WO2000052210A2 (en) 1999-03-01 2000-09-08 Variagenics, Inc. Methods for targeting rna molecules
ID30262A (en) 1999-03-29 2001-11-15 Procter & Gamble LIGAN RECEPTOR OF MELANOKORTIN
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6713280B1 (en) 1999-04-07 2004-03-30 Thomas Jefferson University Enhancement of peptide cellular uptake
US6346264B1 (en) 1999-04-27 2002-02-12 International Health Products And Services Ltd. Supplement for restoring growth hormone levels
DE60026300T2 (en) 1999-05-17 2006-11-16 Conjuchem, Inc., Montreal PROTECTION OF ENDOGENOUS, THERAPEUTICALLY ACTIVE PEPTIDES FROM PEPTIDASE ACTIVITY BY CONJUGATION TO BLOOD COMPONENTS
US20090175821A1 (en) 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US7192713B1 (en) 1999-05-18 2007-03-20 President And Fellows Of Harvard College Stabilized compounds having secondary structure motifs
DE60030970T2 (en) 1999-05-24 2007-09-06 Introgen Therapeutics Inc., Austin METHOD AND COMPOSITIONS FOR NONVIRAL GENE THERAPY FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
AU772752B2 (en) 1999-07-26 2004-05-06 Baylor College Of Medicine Super-active porcine growth hormone releasing hormone analog
US6461634B1 (en) 1999-08-20 2002-10-08 Edward Marshall Food-based delivery of HGH-stimulating and other nutritional supplements
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US6696418B1 (en) 1999-09-01 2004-02-24 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US20020016298A1 (en) 1999-09-01 2002-02-07 Hay Bruce A. Somatostatin antagonists and agonists that act at the sst subtype 2 receptor
US20030181367A1 (en) 1999-09-27 2003-09-25 O'mahony Daniel Conjugates of membrane translocating agents and pharmaceutically active agents
CA2392019A1 (en) 1999-11-22 2001-05-31 Zymogenetics, Inc. Method of forming a peptide-receptor complex with zsig33
US6831155B2 (en) 1999-12-08 2004-12-14 President And Fellows Of Harvard College Inhibition of p53 degradation
US6348558B1 (en) 1999-12-10 2002-02-19 Shearwater Corporation Hydrolytically degradable polymers and hydrogels made therefrom
US6579967B1 (en) 1999-12-14 2003-06-17 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US20030087263A1 (en) 1999-12-16 2003-05-08 Renu Wadhwa Method of screening remedy for cancer with the use of interaction domain of p53 and mortalin
GB0018891D0 (en) 2000-08-01 2000-09-20 Novartis Ag Organic compounds
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
DE10009341A1 (en) 2000-02-22 2001-09-06 Florian Kern Method for antigen-specific stimulation of T lymphocytes
US6495674B1 (en) 2000-02-25 2002-12-17 The Salk Institute For Biological Studies Evectins and their use
US20020002198A1 (en) 2000-04-17 2002-01-03 Parr Tyler B. Chemical synergy to elevate growth hormone release in vertebrates
US6495589B2 (en) 2000-04-28 2002-12-17 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US6897286B2 (en) 2000-05-11 2005-05-24 Zymogenetics, Inc. Zsig33-like peptides
CA2380423A1 (en) 2000-05-17 2001-11-22 Bionebraska, Inc. Peptide pharmaceutical formulations
ES2333097T3 (en) 2000-05-31 2010-02-17 Raqualia Pharma Inc USE OF SECRETAGOGS OF GROWTH HORMONE TO STIMULATE GASTROINTESTINAL MOTILITY.
IL143690A0 (en) 2000-06-19 2002-04-21 Pfizer Prod Inc The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease
IL143942A0 (en) 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
US7166712B2 (en) 2000-07-12 2007-01-23 Philadelphia, Health And Education Corporation Mammalian MDM2 binding proteins and uses thereof
IL144468A0 (en) 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
US7049290B2 (en) 2000-07-28 2006-05-23 Universität Zürich Essential downstream component of the wingless signaling pathway and therapeutic and diagnostic applications based thereon
BR0113178A (en) 2000-08-02 2004-04-06 Theratechnologies Inc Modified biological peptides with increased potency
US20040228866A1 (en) 2000-08-04 2004-11-18 Ludwig Institute For Cancer Research Suppressor genes
US6703382B2 (en) 2000-08-16 2004-03-09 Georgetown University Medical Center Small molecule inhibitors targeted at Bcl-2
AU2001276608A1 (en) 2000-08-30 2002-03-13 Pfizer Products Inc. Sustained release formulations for growth hormone secretagogues
IL145106A0 (en) 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
CN1457257A (en) 2000-09-08 2003-11-19 格莱风治疗公司 Extended native chemical ligation
US6720330B2 (en) 2000-11-17 2004-04-13 Pfizer Inc. Somatostatin antagonists and agonists that act at the SST subtype 2 receptor
US20030074679A1 (en) 2000-12-12 2003-04-17 Schwartz Robert J. Administration of nucleic acid sequence to female animal to enhance growth in offspring
WO2002064790A2 (en) 2000-12-19 2002-08-22 The Johns Hopkins University Jfy1 protein induces rapid apoptosis
US20020091090A1 (en) 2000-12-28 2002-07-11 Cole Bridget M. Somatostatin antagonists and agonists
CU23157A1 (en) 2001-01-03 2006-07-18 Ct Ingenieria Genetica Biotech PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF TISSULAR DANE DUE TO LACK OF BLOOD IRRIGATION ARTERIAL
CA2435563A1 (en) 2001-02-02 2002-08-15 Conjuchem Inc. Long lasting growth hormone releasing factor derivatives
CN1255428C (en) 2001-02-23 2006-05-10 波利弗尔有限公司 Template-fixed peptidomimetics with antimicrobial activity
GB0104588D0 (en) 2001-02-24 2001-04-11 Univ Dundee Novel p-53 inducible protein
DE10109813A1 (en) 2001-03-01 2002-09-12 Thomas Stanislawski Tumor peptide antigen from human mdm2 proto-oncogene
WO2002072597A2 (en) 2001-03-09 2002-09-19 University Of Louisville Helicomimetics and stabilized lxxll peptidomimetics
US7019109B2 (en) 2001-03-16 2006-03-28 The Salk Institute For Bilogical Studies SSTR1-selective analogs
KR20030088494A (en) 2001-04-09 2003-11-19 더 어드미니스트레이터즈 오브 더 튜래인 어듀케이셔널 훤드 Somatostatin agonists
US6368617B1 (en) 2001-05-15 2002-04-09 Reliv' International, Inc. Dietary supplement
WO2002098565A1 (en) 2001-06-05 2002-12-12 Elan Pharma International Limited System and method for milling materials
EP1411924A1 (en) 2001-07-06 2004-04-28 Auckland Uniservices Limited Hypertension treatment
US20050245764A1 (en) 2001-08-08 2005-11-03 Koki Yamashita Process for producing optically active 2-substituted carboxylic acid
EP1578901A4 (en) 2001-09-07 2006-03-29 Baylor College Medicine Linear dna fragments for gene expression
US20040106548A1 (en) 2001-09-07 2004-06-03 Schmidt Michelle A Conformationally constrained labeled peptides for imaging and therapy
US20020045192A1 (en) 2001-09-19 2002-04-18 St. Jude Children's Research Hospital Arf and HDM2 interaction domains and methods of use thereof
EP1312363A1 (en) 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
US20030083241A1 (en) 2001-11-01 2003-05-01 Young Charles W. Use of somatostatin receptor agonists in the treatment of human disorders of sleep hypoxia and oxygen deprivation
CN101157924A (en) 2001-12-11 2008-04-09 人体基因组科学有限公司 Neutrophil leukocyte gene alpha
ES2383796T3 (en) 2001-12-18 2012-06-26 Alizé Pharma SAS Pharmaceutical compositions comprising non-acylated ghrelin for use in the treatment of insulin resistance
EP1321474A1 (en) 2001-12-18 2003-06-25 Universite De Geneve A method for inducing apoptosis
AU2002367160A1 (en) 2001-12-24 2003-07-15 Auckland Uniservices Limited Therapy for growth hormone induced insulin resistance in juveniles with growth disorders
AU2002364364A1 (en) 2001-12-31 2003-07-24 Dana-Farber Cancer Institute, Inc. Method of treating apoptosis and compositions thereof
WO2003059933A2 (en) 2002-01-03 2003-07-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Conformationally constrained c-backbone cyclic peptides
AR038816A1 (en) 2002-02-07 2005-01-26 Baylor College Medicine MODIFIED DEVELOPMENT OF THE PITUITARY GLAND IN THE PROGENIE OF PRESSED FEMALES TREATED WITH THERAPY WITH THE LIBERATING HORMONE OF THE GROWTH HORMONE
JP2006514914A (en) 2002-02-14 2006-05-18 バイエル・フアーマシユーチカルズ・コーポレーシヨン Formulation strategies in the stabilization of peptides in organic solvents and in the dry state
WO2003070892A2 (en) 2002-02-15 2003-08-28 The Regents Of The University Of Michigan Inhibitors of rgs proteins
US20030166138A1 (en) 2002-02-21 2003-09-04 Todd Kinsella Cyclic peptides and analogs useful to treat allergies
AU2003227066A1 (en) 2002-03-26 2003-10-08 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with growth hormone secretagogue receptor (ghs)
US7498134B2 (en) 2002-03-30 2009-03-03 The Trustees Of Columbia University In The City Of New York HAUSP-Mdm2 interaction and uses thereof
US7524630B2 (en) 2002-04-22 2009-04-28 University Of Florida Research Foundation, Inc. Functionalized nanoparticles and methods of use
US20060189511A1 (en) 2002-05-13 2006-08-24 Koblish Holly K Method for cytoprotection through mdm2 and hdm2 inhibition
KR101138643B1 (en) 2002-05-30 2012-04-26 더 스크립스 리서치 인스티튜트 Copper-catalysed ligation of azides and acetylenes
AU2003247435A1 (en) 2002-05-30 2003-12-19 European Molecular Biology Laboratory Combinatorial chemical library ii
US7208154B2 (en) 2002-06-03 2007-04-24 Regents Of The University Of Michigan Methods and compositions for the treatment of MHC-associated conditions
SE0201863D0 (en) 2002-06-18 2002-06-18 Cepep Ab Cell penetrating peptides
WO2004007675A2 (en) 2002-07-15 2004-01-22 The Johns Hopkins University Neuronal and optic nerve gene expression patterns
WO2004009614A2 (en) 2002-07-24 2004-01-29 The Salk Institute For Biological Studies Receptor (sstr4)- selective somatostatin analogs
US20060051846A1 (en) 2002-09-06 2006-03-09 Kaneka Corporation Process for producing l-alpha-methylcysteine derivative
AU2003267124A1 (en) 2002-09-09 2004-03-29 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
CN1688696A (en) 2002-09-18 2005-10-26 蒙特利尔大学医疗中心 GHRH analogues
WO2004026896A2 (en) 2002-09-23 2004-04-01 Medivir Ab Hcv ns-3 serine protease inhibitors
DE60326623D1 (en) 2002-10-07 2009-04-23 Genome Res Ltd P53 BINDING POLYPEPTIDE
CA2500665A1 (en) 2002-10-07 2004-04-22 Zymogenetics, Inc. Methods of regulating body weight
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
DE10393514T5 (en) 2002-10-24 2005-09-29 Dow Global Technologies, Inc., Midland Stabilization of product mixtures from olefin metathesis
ES2336911T3 (en) 2002-11-07 2010-04-19 Kosan Biosciences, Inc. TRANS-9,10-DEHYDROEPOTILONES C AND D, ITS ANALOGS AND PREPARATION PROCEDURES.
MXPA05004743A (en) 2002-11-08 2005-08-03 Hoffmann La Roche Substituted 4-alkoxyoxazol derivatives as ppar agonists.
US20050227932A1 (en) 2002-11-13 2005-10-13 Tianbao Lu Combinational therapy involving a small molecule inhibitor of the MDM2: p53 interaction
US7166575B2 (en) 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
AU2003291967A1 (en) 2002-12-20 2004-07-14 7Tm Pharma A/S Ghrelin receptor inverse agonist for regulation of feeding behaviours
WO2004058804A1 (en) 2002-12-24 2004-07-15 Walter And Eliza Hall Institute Of Medical Research Peptides and therapeutic uses thereof
WO2004063963A2 (en) 2003-01-08 2004-07-29 Xencor, Inc. Novel proteins with altered immunogenicity
CA2513743C (en) 2003-01-28 2013-06-25 Advisys, Inc. Reducing culling in herd animals growth hormone releasing hormone (ghrh)
WO2004067548A2 (en) 2003-01-31 2004-08-12 Theratechnologies Inc. Chemically modified metabolites of regulatory peptides and methods of producing and using same
US7638138B2 (en) 2003-02-21 2009-12-29 Translational Research, Ltd. Compositions for nasal administration of pharmaceuticals
CA2517285A1 (en) 2003-02-26 2004-09-10 Japan Science And Technology Agency Transcriptional factor inducing apoptosis in cancer cell
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
US20070060512A1 (en) 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
WO2004084943A1 (en) 2003-03-19 2004-10-07 Beth Israel Deaconess Medical Center, Inc Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation
US7632920B2 (en) 2003-04-10 2009-12-15 Schering Corporation Soluble, stable form of HDM2, crystalline forms thereof and methods of use thereof
CN100506841C (en) 2003-05-01 2009-07-01 科内尔研究基金会 Method and carrier complexes for delivering molecules to cells
ATE549028T1 (en) 2003-05-15 2012-03-15 Tufts College STABLE ANALOGUES OF GLP-1
EP1628676A1 (en) 2003-05-29 2006-03-01 Theratechnologies Inc. Grf analog compositions and their use
AU2003902743A0 (en) 2003-06-02 2003-06-19 Promics Pty Limited Process for the preparation of cyclic peptides
JP2007500243A (en) 2003-06-09 2007-01-11 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Compositions and methods for enhanced transmucosal delivery of growth hormone
US20090198050A1 (en) 2003-06-18 2009-08-06 Tranzyme Pharma Inc. Macrocyclic Modulators of the Ghrelin Receptor
USRE42013E1 (en) 2003-06-18 2010-12-28 Tranzyme Pharma Inc. Macrocyclic modulators of the ghrelin receptor
USRE42624E1 (en) 2003-06-18 2011-08-16 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7491695B2 (en) 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US7521420B2 (en) 2003-06-18 2009-04-21 Tranzyme Pharma, Inc. Macrocyclic antagonists of the motilin receptor
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2005000876A2 (en) 2003-06-27 2005-01-06 Proteologics, Inc. Ring finger family proteins and uses related thereto
WO2005007675A2 (en) 2003-07-09 2005-01-27 The Scripps Research Institute TRIAZOLE ϵ-AMINO ACIDS
US20070185031A1 (en) 2003-07-14 2007-08-09 Northwestern University Reducing polyglutamine-based aggregation
GB0317815D0 (en) 2003-07-30 2003-09-03 Amersham Health As Imaging agents
WO2005019440A1 (en) 2003-08-20 2005-03-03 Northern Sydney And Central Coast Area Health Service Methods for enhancing embryo viability
CN100475271C (en) 2003-08-20 2009-04-08 加利福尼亚大学董事会 Somatostatin analogs with inhibitory activity to growth hormone release
WO2005027913A1 (en) 2003-09-19 2005-03-31 Pfizer Products Inc. Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and a growth hormone secretagogue
ES2365847T3 (en) 2003-10-03 2011-10-11 Veijlen N.V. USE OF INDOLACTIC ACID DERIVATIVES THAT INCREASE THE SERIAL CONCENTRATION OF IGF-1 FOR THE PREPARATION OF A THERAPEUTIC COMPOSITION FOR THE TREATMENT OF DIFFERENT DISEASES.
WO2005032471A2 (en) 2003-10-03 2005-04-14 Merck & Co., Inc. Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease
GB0323728D0 (en) 2003-10-10 2003-11-12 Royal College Of Surgeons Ie Peptidomimetics and uses thereof
US20070207947A1 (en) 2003-10-16 2007-09-06 Aplagen Gmbh Stabilized Peptides
US20070274915A1 (en) 2003-10-17 2007-11-29 Anjana Rao Modulation Of Anergy And Methods For isolating Anergy-Modulating Compounds
CA2542433A1 (en) 2003-10-20 2005-04-28 Theratechnologies Inc. Use of growth hormone releasing factor analogs in treating patients suffering from wasting
US7273927B2 (en) 2003-11-03 2007-09-25 University Of Massachusetts Mdm2 splice variants
PT1680443E (en) 2003-11-05 2013-12-11 Harvard College Stabilized alpha helical peptides and uses thereof
US20050147581A1 (en) 2003-11-19 2005-07-07 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes having improved stability and therapeutic use of the same
WO2005074521A2 (en) 2004-01-30 2005-08-18 The Trustees Of Columbia University In The City Of New York C-TERMINAL p53 PALINDROMIC PEPTIDE THAT INDUCES APOPTOSIS OF CELLS WITH ABERRANT p53 AND USES THEREOF
US20070161551A1 (en) 2004-02-10 2007-07-12 De Luca Giampiero Methods and compositions for the treatment of lipodystrophy
GB0404731D0 (en) 2004-03-03 2004-04-07 Indp Administrative Inst Nims Method and products for the selective degradation of proteins
US20050203009A1 (en) 2004-03-12 2005-09-15 Bayer Pharmaceuticals Corporation VPAC1 selective antagonists and their pharmacological methods of use
WO2005090388A1 (en) 2004-03-19 2005-09-29 The University Of Queensland Alpha helical mimics, their uses and methods for their production
US20050261201A1 (en) 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
JP2007532495A (en) 2004-04-07 2007-11-15 ガストロテック・ファルマ・アクティーゼルスカブ Use of secretagogues to treat ghrelin deficiency
US7034050B2 (en) 2004-04-28 2006-04-25 Romano Deghenghi Pseudopeptides growth hormone secretagogues
KR20080027969A (en) 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 Novel cis-imidazolines
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
CN100335467C (en) 2004-06-04 2007-09-05 中国科学院上海有机化学研究所 Synthesis of 5-iodo-1,4-twice substituted-1,2,3-trioxazole compound
WO2005118634A2 (en) 2004-06-04 2005-12-15 The Brigham And Women's Hospital, Inc. Helical peptidomimetics with enhanced activity against beta-amyloid production
EP1602663A1 (en) 2004-06-04 2005-12-07 Chiralix B.V. Triazole-linked glycoamino acids and glycopeptides
US7842815B2 (en) 2004-06-17 2010-11-30 Infinity Pharmaceuticals, Inc. Compounds and methods for inhibiting the interaction of BCL proteins with binding partners
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
EP1771205B1 (en) 2004-06-18 2016-10-26 Ambrx, Inc. Novel antigen-binding polypeptides and their uses
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
WO2006020930A2 (en) 2004-08-12 2006-02-23 Sapphire Therapeutics, Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
AU2005277389A1 (en) 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
US7157421B2 (en) 2004-12-27 2007-01-02 Miller Landon C G Piracetam and piracetam analog conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7074775B2 (en) 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7151084B2 (en) 2004-12-27 2006-12-19 Miller Landon C G Compound and method of treating neurogenic conditions using non-steroidal anti-inflammatory drug complexes
US7402652B2 (en) 2004-09-14 2008-07-22 Miller Landon C G Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders
US9598470B2 (en) 2004-10-07 2017-03-21 Craig W. Beattie Compositions and methods to prevent cancer by stabilizing P53 through non MDM2-mediated pathways
KR101228229B1 (en) 2004-10-20 2013-01-31 쎄러테크놀로지스 인코포레이티드 Gh secretagogues and uses thereof
JP4762995B2 (en) 2004-10-29 2011-08-31 シェーリング コーポレイション Substituted 5-carboxamidopyrazoles and substituted [1,2,4] triazoles as antiviral substances
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US20060148715A1 (en) 2004-12-20 2006-07-06 Baylor College Of Medicine Structural requirements for STAT3 binding and recruitment to phosphotyrosine ligands
GB0428187D0 (en) 2004-12-23 2005-01-26 Univ Liverpool Cancer treatment
ES2428869T3 (en) 2005-01-24 2013-11-12 Pepscan Systems B.V. Binding compounds, immunogenic and peptidomimetic compounds
FR2881430B1 (en) 2005-02-01 2010-10-22 Servier Lab NOVEL PEPTIDES INTERACTING WITH ANTI-APOPTOTIC MEMBERS OF THE BCL-2 PROTEIN FAMILY AND USES THEREOF
NZ561215A (en) 2005-02-22 2010-12-24 Univ Michigan Small molecule inhibitors of MDM2 and uses thereof
WO2006101809A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
WO2006103666A2 (en) 2005-03-28 2006-10-05 Yeda Research And Development Co. Ltd. Isolated bid polypeptides, polynucleotides encoding same and antibodies directed thereagainst and methods of using same for inducing cell cycle arrest or apoptosis
WO2006122931A1 (en) 2005-05-20 2006-11-23 Biovitrum Ab (Publ) Beta-carboline derivatives and theri use as ghsr modulators
CA2583345A1 (en) 2005-06-13 2006-12-28 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US20090275648A1 (en) 2005-06-13 2009-11-05 Fraser Graeme L Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US20070020620A1 (en) 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
WO2007009191A1 (en) 2005-07-21 2007-01-25 Newsouth Innovations Pty Limited Method for treating cancer
JP4879265B2 (en) 2005-07-22 2012-02-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ Growth hormone secretagogue
EP1757290A1 (en) 2005-08-16 2007-02-28 Zentaris GmbH Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors
WO2007038678A2 (en) 2005-09-28 2007-04-05 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogs of ghrelin
US20070161544A1 (en) 2006-01-06 2007-07-12 Peter Wipf Selective targeting agents for mitcochondria
WO2007095347A2 (en) 2006-02-13 2007-08-23 The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Methods and compositions related to ghs-r antagonists
US7538190B2 (en) 2006-02-17 2009-05-26 Polychip Pharmaceuticals Pty Ltd Methods for the synthesis of two or more dicarba bridges in organic compounds
US7745573B2 (en) 2006-02-17 2010-06-29 Polychip Pharmaceuticals Pty Ltd. Conotoxin analogues and methods for synthesis of intramolecular dicarba bridge-containing peptides
GB0603295D0 (en) 2006-02-18 2006-03-29 Ardana Bioscience Ltd Methods and kits
CU23592A1 (en) 2006-02-28 2010-11-11 Ct Ingenieria Genetica Biotech METHOD TO PREVENT AND ELIMINATE FIBROSIS AND OTHER FORMS OF PATHOLOGICAL DEPOSIT IN THE FABRICS APPLYING THE GHRP-6 SECRETAGOGO PEPTIDE
JP5325092B2 (en) 2006-03-13 2013-10-23 リアット・ミンツ Cachexia and / or anorexia and / or anorexia-ghrelin splice mutation to treat cachexia and / or malnutrition and / or lipodystrophy and / or muscle wasting and / or appetite-stimulation Use of the body
EP2007716A1 (en) 2006-04-13 2008-12-31 Glaxo Group Limited Aryl and heteroaryl sulphonamides as growth hormone secretagogue receptor agonists
US8536120B2 (en) 2006-04-28 2013-09-17 The Administrators Of The Tulane Educational Fund Ghrelin/growth hormone releasing peptide/growth hormone secretatogue receptor antagonists and uses thereof
GB0611405D0 (en) 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
US7998927B2 (en) 2006-06-23 2011-08-16 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US8084022B2 (en) 2006-06-23 2011-12-27 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US20090326193A1 (en) 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US8173594B2 (en) 2006-06-23 2012-05-08 Aegis Therapeutics, Llc Stabilizing alkylglycoside compositions and methods thereof
US7425542B2 (en) 2006-06-23 2008-09-16 Aegis Therapeutics, Inc. Stabilizing alkylglycoside compositions and methods thereof
KR20090042779A (en) * 2006-06-30 2009-04-30 쉐링 코포레이션 Substituted piperidines that increase p53 activity and the uses thereof
WO2008005266A2 (en) 2006-06-30 2008-01-10 Schering Corporation Method of using substituted piperidines that increase p53 activity
US8088733B2 (en) 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
WO2008008357A1 (en) 2006-07-11 2008-01-17 Harkness Pharmaceuticals, Inc. Methods of treating obesity using satiety factors
JP2009544697A (en) 2006-07-26 2009-12-17 ペプスキャン システムズ ベー．フェー． Immunogenic compounds and protein mimetics
WO2008014216A1 (en) 2006-07-28 2008-01-31 St. Jude Children's Research Hospital Method for treating ocular cancer
US7737174B2 (en) 2006-08-30 2010-06-15 The Regents Of The University Of Michigan Indole inhibitors of MDM2 and the uses thereof
EP2099445B1 (en) 2006-09-04 2010-11-17 University Court of The University of Dundee P53 activating benzoyl urea and benzoyl thiourea compounds
WO2008033557A2 (en) 2006-09-15 2008-03-20 Siemens Medical Solutions Usa, Inc. Click chemistry-derived cyclic peptidomimetics as integrin markers
US7897394B2 (en) 2006-09-21 2011-03-01 Intrexon Corporation Endoplasmic reticulum localization signals
JP2010504298A (en) 2006-09-21 2010-02-12 エフ．ホフマン−ラ ロシュ アーゲー Oxindole derivatives
CN101541341B (en) 2006-09-27 2013-06-05 益普生制药两合公司 Analogs of ghrelin substituted at the N-terminal
WO2008040000A2 (en) 2006-09-28 2008-04-03 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
JP2010505831A (en) 2006-10-05 2010-02-25 ニューヨーク ブラッド センター， インコーポレイテッド Stabilized, therapeutic small helical antiviral peptide
KR100860060B1 (en) 2006-10-12 2008-09-24 한국과학기술연구원 METHOD FOR QUANTITATIVE ANALYSIS OF INTERACTIONS BETWEEN HIF-1ALPHA C-TERMINAL PEPTIDES AND CBP OR p300 PROTEINS AND METHOD OF SCREENING INHIBITORS AGAINST FORMATION OF PROTEIN COMPLEX USING THE SAME
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
CN101631801B (en) 2006-10-16 2013-06-05 索尔克生物学研究院 Receptor (SSTR2)-selective somatostatin antagonists
EP2997973A1 (en) 2006-11-15 2016-03-23 Dana-Farber Cancer Institute, Inc. Stabalized maml peptides and uses thereof
US7932397B2 (en) 2006-11-22 2011-04-26 Massachusetts Institute Of Technology Olefin metathesis catalysts and related methods
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
JP5656407B2 (en) 2006-12-14 2015-01-21 エイルロン セラピューティクス，インコーポレイテッド Bis-sulfhydryl macrocyclic system
WO2008074895A1 (en) 2006-12-21 2008-06-26 Cytos Biotechnology Ag Circular ccr5 peptide conjugates and uses thereof
WO2008092281A1 (en) 2007-01-29 2008-08-07 Polyphor Ltd. Template-fixed peptidomimetics
CA2677045C (en) * 2007-01-31 2016-10-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
BRPI0807046A2 (en) 2007-02-09 2015-05-26 Tranzyme Pharma Inc Compound, pharmaceutical composition, methods of treating a disorder, cardiovascular disease and a patient suffering from reduced or dysfunctional gastrointestinal motility and, kit.
CN101244053B (en) 2007-02-16 2010-12-08 石药集团中奇制药技术（石家庄）有限公司 Novel dispersed system with docetaxel as main component
EP2564862B1 (en) 2007-02-23 2017-08-02 Aileron Therapeutics, Inc. Substituted amino acids for preparing triazole linked macrocyclic peptides
WO2008106507A2 (en) 2007-02-27 2008-09-04 University Of South Florida Mdm2/mdmx inhibitor peptide
US7816324B2 (en) 2007-03-13 2010-10-19 Board Of Regents, The University Of Texas System Composition and method for the treatment of diseases affected by a peptide receptor
AU2008232709C1 (en) 2007-03-28 2015-01-15 President And Fellows Of Harvard College Stitched polypeptides
TWI429436B (en) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc Methods of treating or preventing emesis using growth hormone secretagogues
US8076295B2 (en) * 2007-04-17 2011-12-13 Nanotope, Inc. Peptide amphiphiles having improved solubility and methods of using same
US20080260820A1 (en) 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
ES2637687T3 (en) 2007-05-02 2017-10-16 Dana-Farber Cancer Institute, Inc. BAD peptide of BH3 domain for use in the treatment or delay of the onset of diabetes
AU2008260483A1 (en) 2007-06-01 2008-12-11 Acologix, Inc. High temperature stable peptide formulation
US20090088380A1 (en) 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
RU2007133287A (en) 2007-09-05 2009-03-10 Ионов Иль Давидович (RU) ANTIPOPSORIATIC AGENT AND METHOD OF ITS USE (OPTIONS)
KR20100057640A (en) 2007-09-11 2010-05-31 몬도바이오테크 래보래토리즈 아게 Use of insulin c-peptide, alone or in combination with glp-1, as a therapeutic agent
JP2010539063A (en) 2007-09-11 2010-12-16 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト Use of GRF-1 (1-29) and adrenocorticotropic hormone releasing factor as therapeutic agents
CN101918841B (en) * 2007-09-11 2013-09-11 科德生物工程有限公司 Peptide-lipid constructs and their use in diagnostic and therapeutic applications
KR20100061677A (en) 2007-09-11 2010-06-08 몬도바이오테크 래보래토리즈 아게 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents
EP2197431A4 (en) 2007-09-17 2013-03-27 Olas Pharmaceuticals Inc Modulation of growth hormone, dhea, and cortisol with positive modulators of ampa type glutamate receptors
WO2009037343A1 (en) * 2007-09-21 2009-03-26 Janssen Pharmaceutica Nv Inhibitors of the interaction between mdm2 and p53
JP5783721B2 (en) 2007-09-26 2015-09-24 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド Methods and compositions for modulating BCL-2 family polypeptides
JP5331817B2 (en) 2007-12-03 2013-10-30 イタルファルマコ ソシエタ ペル アチオニ Novel non-selective somatostatin analogues
EP2247298B1 (en) 2007-12-31 2016-08-31 New York University Control of viral-host membrane fusion with hydrogen bond surrogate-based artificial helices
HUE028536T2 (en) 2008-01-07 2016-12-28 Amgen Inc Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP5674476B2 (en) 2008-01-25 2015-02-25 ピー５３ インコーポレイテッド P53 biomarker
CN103951541A (en) 2008-01-25 2014-07-30 波士顿学院董事会 Method for catalyzing metathesis reactons including enantioselective olefin metathesis
EP2926827A3 (en) 2008-02-08 2015-11-04 Aileron Therapeutics, Inc. Therapeutic Peptidomimetic Macrocycles
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
WO2009126292A2 (en) * 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
WO2009137532A1 (en) 2008-05-06 2009-11-12 New York Blood Center Antiviral cell penetrating peptides
EP2285970A4 (en) * 2008-06-03 2011-10-12 Aileron Therapeutics Inc Compositions and methods for enhancing cellular transport of biomolecules
US8343760B2 (en) 2008-06-05 2013-01-01 University Of Maryland, Baltimore p53 activator peptides
US10240138B2 (en) 2008-06-12 2019-03-26 Ipsen Bioinnovation Limited Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
US20110158973A1 (en) 2008-06-12 2011-06-30 Syntaxin Limited Suppression of cancers
US20110171191A1 (en) 2008-06-12 2011-07-14 Syntaxin Limited Suppression of neuroendocrine diseases
US8796216B2 (en) 2008-06-12 2014-08-05 Syntaxin Limited Suppression of neuroendocrine diseases
BRPI0914300B8 (en) 2008-06-25 2021-05-25 Braasch Biotech Llc vaccine for obesity treatment
US20110144306A1 (en) 2008-07-23 2011-06-16 President And Fellows Of Harvard College Ligation of stapled polypeptides
GB0813873D0 (en) 2008-07-30 2008-09-03 Univ Dundee Compounds
US8583380B2 (en) 2008-09-05 2013-11-12 Aueon, Inc. Methods for stratifying and annotating cancer drug treatment options
WO2010033617A2 (en) * 2008-09-16 2010-03-25 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
EP2344520B1 (en) 2008-09-18 2013-11-13 New York University Inhibiting interaction between hif-1a and p300/cbp with hydrogen bond surrogate-based helices
EP2350118B1 (en) 2008-09-19 2016-03-30 Nektar Therapeutics Carbohydrate-based drug delivery polymers and conjugates thereof
CA2737918A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CN102203245A (en) * 2008-09-22 2011-09-28 爱勒让治疗公司 Peptidomimetic macrocycles
BRPI0918948A2 (en) 2008-09-22 2015-12-15 Aileron Therapeutics Inc peptidomimetic macrocycles
WO2010034031A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2342221B1 (en) * 2008-09-22 2018-11-07 Aileron Therapeutics, Inc. Methods for preparing purified polypeptide compositions
AU2009294871A1 (en) 2008-09-22 2010-03-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3401684B1 (en) 2008-10-10 2022-03-16 Dana Farber Cancer Institute, Inc. Chemical modulators of pro-apoptotic bax and bcl-2 polypeptides
JP2010120881A (en) 2008-11-19 2010-06-03 Keio Gijuku PEPTIDE FOR INHIBITING INTERACTION BETWEEN HUMAN CANCER PROTEIN MDM2 AND HUMAN CANCER-INHIBITING PROTEIN p53, AND USE THEREOF
KR101298168B1 (en) 2008-11-21 2013-08-20 충남대학교산학협력단 Chemical inhibitor of snail―ｐ５３ binding and pharmaceutical composition for treating cancer disease comprising the same
CN102223891A (en) 2008-11-24 2011-10-19 爱勒让治疗公司 Peptidomimetic macrocycles with improved properties
WO2010065572A1 (en) 2008-12-04 2010-06-10 The Salk Institute For Biological Studies Sstr1-selective analogs
US9079970B2 (en) 2008-12-09 2015-07-14 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of MCL-1
US20100152114A1 (en) 2008-12-12 2010-06-17 Univ Of Miami And Usa By Dept Of Veterans Affairs Antioxidant activity of GH-RH Antagonists
CA2744088A1 (en) * 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2010083501A2 (en) 2009-01-16 2010-07-22 University Of South Florida Alpha-helix mimetic using a 2,5-oligopyrimidine scaffold
US8217051B2 (en) 2009-02-17 2012-07-10 Hoffmann-La Roche Inc. Spiroindolinone derivatives
US20100239589A1 (en) 2009-02-23 2010-09-23 Salk Institute For Biological Studies Methods and Compositions for Ameliorating Diabetes and Symptoms Thereof
FR2942798B1 (en) 2009-03-05 2011-04-08 Centre Nat Rech Scient PEPTIDES USEFUL FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA
WO2010107485A1 (en) 2009-03-17 2010-09-23 The Trustees Of Columbia University In The City Of New York E3 ligase inhibitors
EP2421548A4 (en) 2009-04-20 2012-09-26 Theratechnologies Inc Use of (hexenoyl trans-3)hgrf(l-44)nh2 and simvastatin in combination therapy
AU2010239125B2 (en) 2009-04-22 2015-05-14 The Walter And Eliza Hall Institute Of Medical Research Structure of the C-terminal region of the insulin receptor alpha-chain and of the insulin-like growth factor receptor alpha-chain
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
US8883721B2 (en) 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US20100303791A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US20100303794A1 (en) 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
WO2011005219A1 (en) 2009-07-07 2011-01-13 Agency For Science, Technology And Research Novel mdm2 binding peptides and uses thereof
AU2010273220B2 (en) 2009-07-13 2015-10-15 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
EA201200321A1 (en) 2009-08-26 2012-09-28 Новартис Аг TETRA-SUBSTITUTED HETEROARRYL COMPOUNDS AND THEIR USE AS MDM2 AND / OR MDM4 MODULATORS
CN102712675A (en) 2009-09-22 2012-10-03 爱勒让治疗公司 Peptidomimetic macrocycles
WO2011041369A1 (en) 2009-09-30 2011-04-07 Tranzyme Pharma, Inc. Salts, solvates, and pharmaceutical compositions of macrocyclic ghrelin receptor agonists and methods of using the same
US8017607B2 (en) 2009-10-14 2011-09-13 Hoffmann-La Roche Inc. N-substituted-pyrrolidines as inhibitors of MDM2-P-53 interactions
CA2777700A1 (en) 2009-10-14 2011-04-21 Aileron Therapeutics, Inc. Improved peptidomimetic macrocycles
AU2010313282A1 (en) 2009-10-30 2012-05-24 Ocera Therapeutics, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
US20120283269A1 (en) 2009-11-04 2012-11-08 Health Research Inc. Method and Compositions for Suppression of Aging
CA2780547C (en) 2009-11-12 2015-02-03 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
US20110118283A1 (en) 2009-11-17 2011-05-19 Qingjie Ding Substituted Pyrrolidine-2-Carboxamides
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
CU24130B1 (en) 2009-12-22 2015-09-29 Novartis Ag ISOQUINOLINONES AND REPLACED QUINAZOLINONES
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
US8658170B2 (en) 2010-01-06 2014-02-25 Joseph P. Errico Combination therapy with MDM2 and EFGR inhibitors
KR101220516B1 (en) 2010-01-21 2013-01-10 연세대학교 산학협력단 Human Adult Stem Cells Secreting Anti-MDM2 and Uses thereof
US8598400B2 (en) 2010-02-08 2013-12-03 Massachusetts Institute Of Technology Efficient methods for Z- or cis-selective cross-metathesis
US8288431B2 (en) 2010-02-17 2012-10-16 Hoffmann-La Roche Inc. Substituted spiroindolinones
WO2011106650A2 (en) 2010-02-27 2011-09-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease
KR20130050938A (en) 2010-04-09 2013-05-16 더 리젠츠 오브 더 유니버시티 오브 미시건 2 biomarkers for mdm2 inhibitors for use in treating disease
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same
US9127088B2 (en) 2010-05-13 2015-09-08 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
MX2012013005A (en) 2010-05-13 2013-02-26 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting g protein-coupled receptor activity.
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
AU2011268256B8 (en) 2010-06-16 2016-12-22 Mcgill University Growth hormone secretatogue receptor antagonists and uses thereof
US20130177979A1 (en) 2010-06-22 2013-07-11 University Of Central Florida Research Foundation, Inc. Methods and compositions for cell permeable stat3 inhibitor
US20110313167A1 (en) 2010-06-22 2011-12-22 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Substituted Heterocycles as Therapeutic agents for treating cancer
CN102958533B (en) 2010-06-24 2016-01-20 印第安纳大学研究及科技有限公司 The medicament that dipeptides connects
CA2796894A1 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
US20130137645A1 (en) 2010-07-19 2013-05-30 Mary S. Rosendahl Modified peptides and proteins
US8975232B2 (en) 2010-07-29 2015-03-10 President And Fellows Of Harvard College Macrocyclic kinase inhibitors and uses thereof
SI2603600T1 (en) * 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2012033525A2 (en) 2010-09-08 2012-03-15 University Of Pittsburgh - Of The Commonwealth System Of Higher Education P53-mdm2 antagonists
US20120065210A1 (en) 2010-09-15 2012-03-15 Xin-Jie Chu Substituted hexahydropyrrolo[1,2-c]imidazolones
EP2431035A1 (en) 2010-09-16 2012-03-21 Æterna Zentaris GmbH Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors
WO2012037519A2 (en) 2010-09-16 2012-03-22 University Of Miami Acceleration of wound healing by growth hormone releasing hormone and its agonists
CN102399284B (en) 2010-09-17 2013-05-29 中国农业大学 Fox growth hormone releasing hormone cDNA and its application
CN102399283B (en) 2010-09-17 2013-05-29 中国农业大学 Mink growth hormone releasing hormone cDNA and application thereof
US20120071499A1 (en) 2010-09-20 2012-03-22 Xin-Jie Chu Substituted Spiro[3H-Indole-3,6'(5'H)-[1H]Pyrrolo[1,2c]Imidazole-1',2(1H,2'H)-diones
US8957026B2 (en) 2010-09-22 2015-02-17 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
WO2012047587A2 (en) 2010-09-27 2012-04-12 Serrata, Llc Mdm2 inhibitors for treatment of ocular conditions
EP2621275B1 (en) 2010-09-30 2018-03-28 St. Jude Children's Research Hospital Aryl-substituted imidazoles
EP2627662B1 (en) 2010-10-13 2015-09-16 Bristol-Myers Squibb Company Methods for preparing macrocycles and macrocycle stabilized peptides
FR2967072B1 (en) 2010-11-05 2013-03-29 Univ Dundee PROCESS FOR IMPROVING INFLUENZA PRODUCTION OF VACCINE AND SEEDS
US10822374B2 (en) * 2010-11-12 2020-11-03 Dana-Farber Cancer Institute, Inc. Cancer therapies and diagnostics
EA201390682A1 (en) 2010-11-12 2014-01-30 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган SPIROOXINDAL ANTAGONISTS MDM2
WO2012076513A1 (en) 2010-12-09 2012-06-14 F. Hoffmann-La Roche Ag 3-cyano-1-hydroxymethyl-2-phenylpyrrolidine derivatives as inhibitors of mdm2-p53 interactions useful for the treatment of cancer
WO2012083078A2 (en) 2010-12-15 2012-06-21 The Research Foundation Of State University Of New York Croos-linked peptides and proteins, methods of making same, and uses thereof
WO2012083181A1 (en) 2010-12-16 2012-06-21 Indiana University Research And Technology Corporation Alpha helix mimetics and methods for using
WO2012080389A1 (en) 2010-12-16 2012-06-21 Roche Glycart Ag Combination therapy of an afucosylated cd20 antibody with a mdm2 inhibitor
US20130253011A1 (en) 2010-12-17 2013-09-26 Syngenta Participations Ag Insecticidal compounds
US20130302909A1 (en) 2011-01-14 2013-11-14 Theratechnologies Inc. Assessment of igf-1 levels in hiv-infected subjects and uses thereof
JP5950587B2 (en) 2011-02-28 2016-07-13 キヤノン株式会社 Method for producing porous glass and method for producing optical member
US8987412B2 (en) 2011-03-04 2015-03-24 New York University Hydrogen bond surrogate macrocycles as modulators of Ras
WO2012121057A1 (en) 2011-03-09 2012-09-13 Jitsubo株式会社 Novel cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method
SI2684880T1 (en) 2011-03-10 2018-08-31 Daiichi Sankyo Company, Limited Dispiropyrrolidine derivative
AU2012249301A1 (en) 2011-04-29 2013-11-21 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
WO2012173846A2 (en) 2011-06-06 2012-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2721061A4 (en) 2011-06-17 2014-11-05 Harvard College Stabilized variant maml peptides and uses thereof
US9487562B2 (en) 2011-06-17 2016-11-08 President And Fellows Of Harvard College Stabilized polypeptides as regulators of RAB GTPase function
GB201110390D0 (en) 2011-06-20 2011-08-03 Medical Res Council Compounds for use in stabilising p53 mutants
US20120328692A1 (en) 2011-06-24 2012-12-27 University Of Maryland, Baltimore Potent d-peptide antagonists of mdm2 and mdmx for anticancer therapy
US20130123196A1 (en) 2011-08-31 2013-05-16 New York University Thioether-, ether-, and alkylamine-linked hydrogen bond surrogate peptidomimetics
US9517252B2 (en) 2011-09-09 2016-12-13 Agency For Science, Technology And Research p53 activating peptides
AU2012316055B2 (en) 2011-09-27 2016-05-12 Amgen Inc. Heterocyclic compounds as MDM2 inhibitors for the treatment of cancer
TWI643868B (en) 2011-10-18 2018-12-11 艾利倫治療公司 Peptidomimetic macrocycles
WO2013059530A2 (en) 2011-10-18 2013-04-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
WO2013062923A1 (en) 2011-10-28 2013-05-02 Merck Sharp & Dohme Corp. MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF
US9408885B2 (en) 2011-12-01 2016-08-09 Vib Vzw Combinations of therapeutic agents for treating melanoma
CA2761253A1 (en) 2011-12-07 2013-06-07 Vib Vzw Combinations of therapeutic agents for treating melanoma
US9464125B2 (en) 2012-02-03 2016-10-11 The Trustees Of Princeton University Engineered potent cytotoxic stapled BH3 peptides
KR102112373B1 (en) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles
US8987414B2 (en) * 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
WO2013166319A1 (en) 2012-05-02 2013-11-07 Kansas State University Research Foundation Macrocyclic and peptidomimetic compounds as broad-spectrum antivirals against 3c or 3c-like proteases of picornaviruses, caliciviruses and coronaviruses
ES2742285T3 (en) 2012-07-31 2020-02-13 Novartis Ag Markers associated with sensitivity to human double minute inhibitors 2 (MDM2)
AU2013325099B2 (en) 2012-09-25 2018-11-15 The Walter And Eliza Hall Institute Of Medical Research Structure of insulin in complex with n- and c-terminal regions of the insulin receptor alpha-chain
RS61957B1 (en) 2012-09-26 2021-07-30 Harvard College Proline-locked stapled peptides and uses thereof
US20150225471A1 (en) 2012-10-01 2015-08-13 President And Fellows Of Harvard College Stabilized polypeptide insulin receptor modulators
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
WO2014115080A1 (en) 2013-01-22 2014-07-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction
JP6266659B2 (en) 2013-02-28 2018-01-24 アムジエン・インコーポレーテツド Benzoic acid derivative MDM2 inhibitors for the treatment of cancer
WO2014138429A2 (en) 2013-03-06 2014-09-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and use thereof in regulating hif1alpha
WO2014197821A1 (en) 2013-06-06 2014-12-11 President And Fellows Of Harvard College Homeodomain fusion proteins and uses thereof
EP3008081B1 (en) 2013-06-14 2017-08-30 President and Fellows of Harvard College Stabilized polypeptide insulin receptor modulators
US20160022720A1 (en) 2013-08-02 2016-01-28 Children's Hospital Medical Center Compositions and methods for treating disease states associated with activated t cells and/or b cells
US20160244494A1 (en) 2013-10-01 2016-08-25 President And Fellows Of Harvard College Stabilized polypeptides and uses thereof
KR102283895B1 (en) 2013-12-23 2021-07-30 노파르티스 아게 Pharmaceutical combinations
KR20160100975A (en) 2013-12-23 2016-08-24 노파르티스 아게 Pharmaceutical combinations
US20170114098A1 (en) 2015-09-03 2017-04-27 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
JP2018528217A (en) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Peptidomimetic macrocycles as modulators of MCL-1
KR20180128022A (en) 2016-03-21 2018-11-30 에일러론 테라퓨틱스 인코포레이티드 A companion diagnostic tool for peptidomimetic giant rings
WO2017205786A1 (en) 2016-05-27 2017-11-30 Aileron Therapeutics, Inc. Cell permeable peptidomimetic macrocycles
WO2017218949A2 (en) 2016-06-17 2017-12-21 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Also Published As

Publication number Publication date
CN112500466A (en) 2021-03-16
TWI654207B (en) 2019-03-21
AU2013221432A1 (en) 2014-08-14
KR102112373B1 (en) 2020-05-18
RU2014137107A (en) 2016-04-10
ES2817877T3 (en) 2021-04-08
IL233710B (en) 2019-02-28
US20220000968A1 (en) 2022-01-06
PH12014501844B1 (en) 2014-11-17
PH12014501844A1 (en) 2014-11-17
TW201339177A (en) 2013-10-01
US8927500B2 (en) 2015-01-06
JP2020109106A (en) 2020-07-16
CA2862038C (en) 2021-05-25
IL233710A0 (en) 2014-09-30
JP6694459B2 (en) 2020-05-13
ZA201405691B (en) 2022-05-25
CA2862038A1 (en) 2013-08-22
EP2822572A4 (en) 2015-11-04
MX2014009880A (en) 2014-11-10
EP2822572A1 (en) 2015-01-14
SG10201606775YA (en) 2016-10-28
WO2013123266A1 (en) 2013-08-22
US20230119612A1 (en) 2023-04-20
US20170281720A1 (en) 2017-10-05
BR112014020103A2 (en) 2018-10-09
AU2013221432B2 (en) 2018-01-18
US9505804B2 (en) 2016-11-29
JP2015509940A (en) 2015-04-02
CN114853866A (en) 2022-08-05
HK1205455A1 (en) 2015-12-18
RU2642299C2 (en) 2018-01-24
US20190343914A1 (en) 2019-11-14
CN107216380A (en) 2017-09-29
JP2018111708A (en) 2018-07-19
CN112500466B (en) 2022-05-03
EP2822572B1 (en) 2020-06-10
RU2017145921A (en) 2019-02-21
US10213477B2 (en) 2019-02-26
MX362492B (en) 2019-01-21
US20130274205A1 (en) 2013-10-17
JP6450191B2 (en) 2019-01-09
CN104159595A (en) 2014-11-19
NZ627528A (en) 2016-05-27
US10967042B2 (en) 2021-04-06
EP3769776A1 (en) 2021-01-27
AR089993A1 (en) 2014-10-01
KR20140122759A (en) 2014-10-20
AU2018202672A1 (en) 2018-05-10
US20150051155A1 (en) 2015-02-19

Similar Documents

Publication Publication Date Title
HK1205455A1 (en) Peptidomimetic macrocycles
IL254716B (en) Zinc-lysine complex
HK1205454A1 (en) Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
HK1210167A1 (en) Macrocycle picolinamides as fungicides -2-
HK1208463A1 (en) Macrocyclic picolinamides as fungicides -2-
HK1208034A1 (en) Macrocyclic picolinamides as fungicides -2-
PL2603600T3 (en) Peptidomimetic macrocycles
EP2768518A4 (en) Peptidomimetic macrocyles
EP2868552A4 (en) Vehicle-cabin body structure
PL3181128T3 (en) Nilotinib pharmaceuticalcomposition
GB201204792D0 (en) Detection techniques
HK1180931A1 (en) An electro-pulsograph
HK1208874A1 (en) Cyclosporin nalogs
EP2911673A4 (en) Combination
EP2908841A4 (en) New antiviral macrocycles
HK1189639A1 (en) Planking arrangement
EP2906215A4 (en) Combinations
EP2813390A4 (en) Armrest
ZA201406931B (en) Integrated desk-and-chair unit
GB201216350D0 (en) Hatch
GB2508723B (en) Seat
EP2925728A4 (en) Combination
PL2800497T3 (en) Lifting-recliner seating unit
EP2908816A4 (en) Combination
EP2908815A4 (en) Combination